Although there may be significant upfront costs associated with the development and implementation of epigenetic interventions, advancements in technology, regulatory processes, and healthcare delivery models can help improve the financial feasibility and ensure that treatment outcomes are affordable for the general population in the long term.
← all excerpts
Human Aging and Age-Related Diseases: From Underlying Mechanisms to Pro-Longevity Interventions.
1
—
—